U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07438509) titled 'Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema' on Feb. 23.
Brief Summary: This randomized controlled trial (RCT) aims to evaluate the efficacy and safety of Crisaborole 2% cream compared with placebo in patients with mild to moderate atopic dermatitis (AD), also known as atopic eczema. AD is a chronic inflammatory skin condition characterized by itching, redness, and recurrent flares that can significantly impair quality of life.
Eligible participants aged 12 to 50 years with mild to moderate AD will be randomly assigned to receive either Crisaborole 2% cream or a placebo cream applied twice dail...